A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)

George R. Blumenschein, Egbert Frederik Smit, David Planchard et al. · Annals of Oncology · 2015

Cited by 349 works. doi:10.1093/annonc/mdv072 Open-access PDF

Authors

References